by Gene-Eden-VIR/Novirin Holds Promising Potential for Coronavirus Treatment
The coronavirus (COVID-19) outbreak has caused a significant threat to the global health, resulting in surging fatalities. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are capitalizing on the ongoing coronavirus pandemic to increase its trials with Gene-Eden-VIR/Novirin that holds promising potentials for coronavirus treatment. Gene-Eden-VIR/Novirin is a patented herbal broad-spectrum antiviral treatment that has shown clinical evidence for HPV and cytomegalovirus treatment. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing awareness for Gene-Eden-VIR/Novirin.
Gene-Eden-VIR/Novirin is being currently tested for COVID-19, since coronavirus is closely related to the human Severe Acute Respiratory Syndrome (SARS-CoV), owing to its high sequence identity. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their trials in several existing drugs that are found effective against RNA viruses such as the coronavirus.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111861
Nanotechnology Improves Pharmacological Techniques in Human Papillomavirus and Cytomegalovirus Therapeutics Market
Human papillomavirus (HPV) is one of key drivers responsible for most cervical cancer cases worldwide. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are tapping opportunities in nanotechnology for the treatment of viral infection and cancer. Such efforts of companies are reflecting in revenue growth for human papillomavirus therapeutics. As such, DNA Nano-based drug carriers are being highly publicized, owing to its bioavailability and these drugs are gaining prominence in antiviral and anticancer drugs of the human papillomavirus and cytomegalovirus therapeutics market.
AS1411 is a G-quadruplex (G4)-forming DNA oligonucleotide that is found at high levels on the surface of cancer cells. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their efforts in clinical trials for AS1411, since the protein holds promising potentials pharmacology and cancer treatment.
Ganciclovir and Cidofovir Highly Preferred Treatments for Cytomegalovirus
Ganciclovir is considered as the gold standard for active cytomegalovirus treatment. As such, Ganciclovir/Valganciclovir is estimated to dictate the highest revenue among all drugs in the cytomegalovirus therapeutics sector. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing their production capabilities of intravenous ganciclovir, especially for immunocompromised patients.
To understand how our report can bring difference to your business strategy, Ask for a brochure
On the other hand, second-line drugs such as Cidofovir and Foscarnet are also being highly preferred in the human papillomavirus and cytomegalovirus therapeutics market. These drugs help to inhibit the viral DNA polymerase over cellular polymerases. Acyclovir is another promising drug used in the treatment of cytomegalovirus and is an approved treatment in the European Union. As such, Europe is anticipated to dictate the second-highest revenue among all regions in the human papillomavirus and cytomegalovirus therapeutics market.
Longer Screening Intervals Reduce Uncertainty Associated with Vaccines
There is a growing demand for vaccines in the human papillomavirus and cytomegalovirus therapeutics market. However, researchers have found that the follow-up time has been relatively short over the years to determine the efficacy of Gardasil and Cervarix vaccines for HPV treatment. This explains why the HPV therapeutics sector is estimated to progress at a modest CAGR of ~4% during the forecast period. As such, an unrepresentative population of women older than the usual target age group of 9-13 years is also hampering growth of the human papillomavirus and cytomegalovirus therapeutics market.
Vaccines meant to treat cervical cancer usually takes decades to develop. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics should increase their screening intervals to reduce uncertainty associated with the efficacy of vaccines. Moreover, the demand for vaccines is predicted to rise in the human papillomavirus and cytomegalovirus therapeutics market due to high survival rates of HPV patients. For instance, renowned biotech executive Michael Becker who died last year due to HPV, laid emphasis on the potential of vaccines for the treatment of HPV.
human papillomavirus cytomegalovirus therapeutics market segmentation
Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Papillomavirus and Cytomegalovirus Therapeutics Market
Analysts’ Viewpoint
Gene-Eden-VIR/Novirin is predicted to create a ray of hope for coronavirus therapeutics, owing to its efficacy in HPV and cytomegalovirus treatment. AS1411 is found to be well tolerated in therapeutic activities for DNA Nano-based drug carriers.
Companies in the human papillomavirus and cytomegalovirus therapeutics market are becoming increasingly aware about one dose of HPV vaccine, which is relatively more effective than multiple doses. Prioritizing single-dose vaccination in less privileged countries is generating incremental opportunities for companies, since it eliminates the issue of increased spending associated with multiple doses for cancer patients. However, unrepresentative population and uncertainty in trials for HPV vaccines are inhibiting market growth. Hence, companies should aim at extending their screening intervals and target appropriate age groups to validate the efficacy of HPV vaccines.
Human Papillomavirus and Cytromegalovirus Therapeutics Market: Overview
The global human papillomavirus and cytromegalovirus therapeutics market comprises drugs and their applications
Human papillomavirus has over 100 strains responsible for various genital warts as well as cancers affecting genital and oral region of the body. Drugs for treatment of HPV include immunomodulators, keratolytics, antineoplastics, and sinecatechins.
Cytomegalovirus (CMV) is a double-stranded DNA virus and is a member of the Herpesviridae family, which can cause various diseases and infections. Major drug classes for these infections include antiviral drugs such as Ganciclovir, Valganciclovir, and Foscavir.
Therapeutic options primarily cure symptoms of the disease and are effective antiviral options. These drugs are available in the market as both branded as well as generics.
Rise in prevalence of HPV infections in developing and underdeveloped countries, grants from governments & international organizations for cancer treatment, and proactive government initiatives are the major factors driving the human papillomavirus and cytromegalovirus therapeutics market
In September 2018, the U.S. Agency for International Development (USAID) obtained Congressional approval to invest US$ 1.2 Mn in funds from fiscal year 2017 to support the integration of cervical cancer preventative services into existing voluntary family planning and reproductive health programs in Malawi and Mozambique, two low-income countries with some of the highest rates of cervical cancer in the world
Recurring nature of cytomegalovirus infections and diseases is a major factor fueling the growth of the global human papillomavirus and cytromegalovirus therapeutics market
Moreover, development of novel molecules for CMV infection and product approval by regulatory bodies boosts the growth of the global human papillomavirus and cytromegalovirus therapeutics market
Market Segmentation: Human Papillomavirus and Cytomegalovirus Therapeutics Market
In terms of drug class, the global human papillomavirus and cytromegalovirus therapeutics market has been classified into immunomodulators, keratolytics, antineoplastics, and sinecatechins
Based on application, the global human papillomavirus and cytromegalovirus therapeutics market has been categorized into genital warts, genital cancer, oral papillomas, and others
In terms of distribution channel, the global human papillomavirus and cytromegalovirus therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies
Based on drug class, the global human papillomavirus and cytromegalovirus therapeutics market has been split into Ganciclovir/Valganciclovir, Foscavir (Foscarnet), Cidofovir (Vistide), Letermovir (Prevymis), and others
In terms of application, the global human papillomavirus and cytromegalovirus therapeutics market has been segmented into retinitis, gastrointestinal ulcer, pneumonia, encephalitis, and others
Each of the global human papillomavirus and cytomegalovirus therapeutics market segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
The global human papillomavirus and cytomegalovirus therapeutics market report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.
Regional Overview: Human Papillomavirus and Cytomegalovirus Therapeutics Market
In terms of region, the global human papillomavirus and cytomegalovirus therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
North America dominated the global human papillomavirus and cytomegalovirus therapeutics market in 2018
The current and future sizes of the human papillomavirus and cytomegalovirus therapeutics market in terms of revenue (US$ Mn) in these regions and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027.
The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process
Major Players
The global human papillomavirus and cytomegalovirus therapeutics market report concludes with the company profiles section that includes key information about the major players in the market
Key players analyzed in the human papillomavirus and cytomegalovirus therapeutics market report are
- Merck & Co., Inc.
- Bausch & Lomb Incorporated (Bausch Health Companies, Inc.)
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Clinigen Group plc
- Pfizer, Inc.
- Cipla Inc.
Key Questions Answered in Human Papillomavirus and Cytomegalovirus Therapeutics Market Report
- What is the sales/revenue generated by each drug class, application, and distribution channel segment of the global human papillomavirus and cytomegalovirus therapeutics market across all regions during the forecast period?
- What are the opportunities in the global human papillomavirus and cytomegalovirus therapeutics market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is likely to expand at the fastest CAGR during the forecast period?
- Which human papillomavirus and cytomegalovirus therapeutics drug class, application, and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the market share or position of different companies operating in the global market in 2018?
Human Papillomavirus and Cytomegalovirus Therapeutics Market – Segmentation
Drug Class
- Human
- Papillomavirus
- Therapeutics
- Immunomodulators
- Keratolytics
- Antineoplastics
- Sinecatechins
- Cytomegalovirus
- Therapeutics
- Ganciclovir/Valganciclovir
- Foscavir (Foscarnet)
- Cidofovir (Vistide)
- Letermovir (Prevymis)
- Others
Application
- Human
- Papillomavirus Therapeutics
- Genital Warts
- Genital Cancer
- Oral Papillomas
- Others
- Cytomegalovirus
- Therapeutics
- Retinitis
- Gastrointestinal Ulcer
- Pneumonia
- Encephalitis
- Others
Distribution Channel
- Human
- Papillomavirus
- Therapeutics
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Cytomegalovirus
- Therapeutics
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North
- America
- Europe
- Asia
- Pacific
- Latin
- America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111861/2900
